Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis

Bibliographic Details
Main Authors:	Oliver, ME, Poole, S, Borg, C, Connolly, C, Pavord, ID, Hinks, TSC, Couillard, S
Format:	Conference item
Language:	English
Published:	BMJ Publishing Group 2021

Similar Items

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
by: Couillard, S, et al.
Published: (2021)

Asthma in pregnancy: An update
by: Couillard, S, et al.
Published: (2020)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
by: Moran, AM, et al.
Published: (2020)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
by: Couillard, S, et al.
Published: (2020)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
by: Moran, A, et al.
Published: (2020)

How I do it: workup of severe asthma
by: Couillard, S, et al.
Published: (2021)

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
by: Couillard, S, et al.
Published: (2022)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
by: Couillard, S, et al.
Published: (2021)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
by: Couillard, S, et al.
Published: (2021)

The upper and lower airway microbiome in severe asthma
by: Jabeen, M, et al.
Published: (2022)

Azithromycin in viral infections
by: Oliver, ME, et al.
Published: (2020)

To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments
by: Couillard, S, et al.
Published: (2021)

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
by: Lavoie, G, et al.
Published: (2024)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
by: Couillard, S, et al.
Published: (2022)

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids while on monoclonal antibody therapy: protocol for a prospective observational study (BOOST)
by: Howell, I, et al.
Published: (2023)

Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma
by: Couillard, S, et al.
Published: (2021)

Biological therapies for asthma
by: Couillard Castonguay, S, et al.
Published: (2021)

Treatment options in type-2 low asthma
by: Hinks, TSC, et al.
Published: (2020)

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
by: Couillard Castonguay, S, et al.
Published: (2022)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
by: Howell, I, et al.
Published: (2024)

Non-typeable Haemophilus influenzae airways infection: the next treatable trait in asthma?
by: Hinks, TSC, et al.
Published: (2022)

Species‐level, metagenomic and proteomic analysis of microbe‐immune interactions in severe asthma
by: Jabeen, MF, et al.
Published: (2024)

The Lancet COPD Commission: broader questions remain
by: Petousi, N, et al.
Published: (2023)

Identifying bacterial airways infection in stable severe asthma using Oxford nanopore sequencing technologies
by: Jabeen, MF, et al.
Published: (2022)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
by: Shrimanker, R, et al.
Published: (2017)

Azithromycin for mild-to-moderate COVID-19 - Authors' reply
by: Hinks, TSC
Published: (2021)

Boosting MAIT cells as immunotherapy: Context is everything
by: Hinks, TSC
Published: (2020)

Epithelial immune activation and intracellular invasion by non-typeable Haemophilus influenzae
by: Brown, MA, et al.
Published: (2023)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
by: Couillard, S, et al.
Published: (2021)

Prevalence of cardiovascular disease risk amongst the population eligible for the NHS Health Check Programme.
by: Dalton, A, et al.
Published: (2013)

Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework
by: Couillard, S, et al.
Published: (2022)

Anti-IL-4/IL-13 for the treatment of asthma: the story so far
by: Moran, A, et al.
Published: (2020)

The effect of oral corticosteroids on circulating type-2 cytokine producing cells in patients with severe eosinophilic asthma
by: Hynes, G, et al.
Published: (2018)

Sputum Il-17a levels correlate with biomarkers of non-eosinophilic inflammation in patients with asthma
by: Hynes, G, et al.
Published: (2017)

The relationship between clinical outcomes and medication adherence in difficult-to-control asthma.
by: Murphy, A, et al.
Published: (2012)

MAIT cells and the microbiome
by: Jabeen, MF, et al.
Published: (2023)

Data on Medicare eligibility and cancer screening utilization
by: Christian P. Meyer, et al.
Published: (2016-06-01)

Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight
by: Howell, I, et al.
Published: (2023)

School-based asthma therapy: Improving medication adherence, asthma control, and health care utilization
by: Kimberly Arcoleo, PhD, MPH, et al.
Published: (2025-05-01)

Cytometric gating stringency impacts on studies of type 2 innate lymphoid cells in asthma
by: Hinks, T, et al.
Published: (2017)